Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview 7 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development 24 CASI Pharmaceuticals Inc 24 Daiichi Sankyo Co Ltd 24 Ildong Pharmaceutical Co Ltd 25 NewLink Genetics Corp 25 OncoImmune Inc 26 Peloton Therapeutics Inc 26 RXi Pharmaceuticals Corp 27 Sorrento Therapeutics Inc 27 Vascular Biogenics Ltd 28 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles 29 A-503451A - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BC-001 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CASI-2ME2 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CRLX-101 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Echinomycin - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 HS-1793 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 IDF-11774 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 KCN-1 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 MPT-0B098 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Inhibit HIF-1 Alpha for Oncology - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 SR-16388 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 TR-764 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VB-411 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products 59 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products 62 Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development Milestones 63 Featured News & Press Releases 63 Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting 63 Aug 18, 2016: Cerulean Announces Reduction in Force 64 Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma 64 Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer 65 Jun 22, 2016: Cerulean Announces Publication in Cancer Research 65 Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology 66 May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference 66 May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA 67 Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference 68 Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer 68 Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue 70 Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting 71 Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 73 Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 74 Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77

List of Tables Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Number of Products under Investigation by Universities/Institutes, H2 2017 16 Products under Investigation by Universities/Institutes, H2 2017 17 Number of Products by Stage and Mechanism of Actions, H2 2017 19 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 23 Pipeline by CASI Pharmaceuticals Inc, H2 2017 24 Pipeline by Daiichi Sankyo Co Ltd, H2 2017 25 Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017 25 Pipeline by NewLink Genetics Corp, H2 2017 26 Pipeline by OncoImmune Inc, H2 2017 26 Pipeline by Peloton Therapeutics Inc, H2 2017 27 Pipeline by RXi Pharmaceuticals Corp, H2 2017 27 Pipeline by Sorrento Therapeutics Inc, H2 2017 28 Pipeline by Vascular Biogenics Ltd, H2 2017 28 Dormant Products, H2 2017 59 Dormant Products, H2 2017 (Contd..1), H2 2017 60 Dormant Products, H2 2017 (Contd..2), H2 2017 61 Discontinued Products, H2 2017 62 List of Figures Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Top 10 Indications, H2 2017 10 Number of Products by Mechanism of Actions, H2 2017 18 Number of Products by Stage and Mechanism of Actions, H2 2017 18 Number of Products by Routes of Administration, H2 2017 20 Number of Products by Stage and Routes of Administration, H2 2017 20 Number of Products by Molecule Types, H2 2017 22 Number of Products by Stage and Molecule Types, H2 2017 22

CASI Pharmaceuticals Inc Daiichi Sankyo Co Ltd Ildong Pharmaceutical Co Ltd NewLink Genetics Corp OncoImmune Inc Peloton Therapeutics Inc RXi Pharmaceuticals Corp Sorrento Therapeutics Inc Vascular Biogenics Ltd